Clinical trial
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
NCT02952989
Study timeline
Study start (actual)2017-02-23Date precision: day
Registry last updated2019-07-19
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Carcinoma, Non-Small-Cell Lungunresolved
Carcinoma, Renal Cellunresolved
Breast Neoplasmsunresolved
Urinary Bladder Neoplasmunresolved
Colorectal Neoplasmsunresolved
Gastric Adenocarcinomaunresolved
Gastroesophageal Junction Adenocarcinomaunresolved
Interventions
SGN-2FFDRUG
pembrolizumabDRUG · verified · RxNorm: pembrolizumab
Sponsors & collaborators
Seagen Inc.lead sponsor
Mapped research locations
HoustonTexas, United States1BostonMassachusetts, United States1AtlantaGeorgia, United States1NashvilleTennessee, United States1SeattleWashington, United States1BirminghamAlabama, United States1PortlandOregon, United States1DurhamNorth Carolina, United States1AuroraColorado, United States1DetroitMichigan, United States1DuarteCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02952989 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.